Home Markets Earnings Estimate Forecast on Becton, Dickinson and Company(BDX)

Earnings Estimate Forecast on Becton, Dickinson and Company(BDX)


Becton, Dickinson and Company(BDX): For the most recent quarter end, Becton, Dickinson and Company reported Annual Earnings of $2.33. Based on the filings, last years Annual Earnings was, $8.59. For the most recent quarter end, BDX reported a surprise Earnings per Share of 10.43% . The consensus estimate for current quarter is $2.24 and for the current fiscal year, the estimate is $9.42. For the Next fiscal year, the estimate is $10.38 based on the consensus. Franklin Lakes based Becton, Dickinson and Company Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on May 04, 2017.

Becton, Dickinson and Company has received $2.24 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 9 Financial Advisor in the Stock Trading Firms. Among 9 Analysts, Bottom line EPS Estimate for the current quarter is $2.11 while the top line estimate is $2.32 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 2.85%. Becton, Dickinson and Company reported better than expected with a surprise EPS of 10.43% or $0.22 during its most recent quarterly earnings. The Actual EPS was $2.33 compared to the Estimated EPS of $2.11. According to the corporate earnings calendar, Becton, Dickinson and Company will release next earnings on May 04, 2017 with an estimated EPS consensus of $2.24. Based on the consensus of stock financial advisors the stock has a price target of $189.54. Current year estimate on EPS consensus is $9.42. The Estimated EPS rate for Long term growth is $9.9.

Becton, Dickinson and Company has a Price to Earnings ratio of 20.27 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 5.12. For the Most Recent Fiscal Year, Becton, Dickinson and Company has a price to cash ratio of 12.99. For the Trailing twelve month period, company showed a Net Profit Margin of 10.54% and Return on Equity of the stock is 25.25%.

Becton, Dickinson and Company last declared its Dividend on Dec 07, 2016. For Dividend Investing Stock Market Traders Becton, Dickinson and Company has a Dividend Yield of 1.6% with an Annual Dividend of $2.92. It has a Payout Ratio of 0.33 and the change in Dividend payout ratio is -0.02.

Becton Dickinson and Co Last issued its quarterly earnings results on Feb 2, 2017. The company reported $2.33 EPS for the quarter, beating the analyst consensus estimate by $ 0.21. Analyst had a consensus of $2.12. The company had revenue of $2922.00 million for the quarter, compared to analysts expectations of $2860.52 million. The companys revenue was down -2.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.96 EPS.

Company has reported several Insider transactions to the SEC, on Feb 16, 2017, Jeffrey S Sherman (Sr. VP and General Counsel) sold 31,464 shares at 180.03 per share price.On Feb 15, 2017, Alexandre Conroy (Executive Vice President) sold 8,500 shares at 177.86 per share price.On Dec 16, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,793 shares at 168.82 per share price.

Becton, Dickinson and Company (NYSE:BDX) witnessed a decline in the market cap on Wednesday as its shares dropped 0.04% or 0.07 points. After the session commenced at $181.33, the stock reached the higher end at $182.58 while it hit a low of $181.1275. With the volume soaring to 649,887 shares, the last trade was called at $181.95. The company has a 52-week high of $182.65. The company has a market cap of $38,724 million and there are 212,825,090 shares in outstanding. The 52-week low of the share price is $144.73.

Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BDs operations consist of three worldwide business segments: Medical Systems, Biosciences, and Preanalytical Solutions.



Please enter your comment!
Please enter your name here